InvestorsHub Logo
icon url

RealinvestDD

02/27/20 10:10 AM

#57645 RE: Saltz #57643

When people start their lives with fraud and theft it will end up the same way it start
icon url

Eng62

02/27/20 10:32 AM

#57648 RE: Saltz #57643

Oooo it's not a story it's fact. One deadline missed after another. Experience would never have these many issues. If it was all about the drug and company why such a outrageous salary.

GL
icon url

edro

02/27/20 12:11 PM

#57662 RE: Saltz #57643

Great,thanks Saltz for keeping it real.
icon url

Eng62

02/27/20 1:06 PM

#57665 RE: Saltz #57643

How do you call it a surface story? All facts regarding missed deadlines, exuberant amount of meaningless pumping pr's, outlandish ceo salary are facts.

Big phrama would of been knocking at CYDY's door years ago with some sort of offer. Fact it trades in the otc with zero revenues is managements failure. Share selling, fund raising will continue.

GL

icon url

Eng62

02/27/20 1:07 PM

#57666 RE: Saltz #57643

A BLA is submitted after an investigational new drug has been approved. If the Form 356h is missing information, the FDA will reply within 74 days. A BLA asserts that the product is "safe, pure, and potent", the manufacturing facilities are inspectable, and each package of the product bears the license number.

icon url

tonysd57

02/27/20 5:19 PM

#57686 RE: Saltz #57643

Saltz:
Well done and on point. However much of this nonsense and hand to mouth funding will be a distant memory when we up list- which could come sooner rather than later if management would consider a miniscule 1/2 RS once we're on solid footing in $2.00- $2.25 range. The NASDAQ is heaven sent for non revenue biotech companies and would love to see us at $4.00+ when the jump is made.

Companies ( and this was in a quick 15 minute search) like AXSM, KOD, CNST,XBIT,CUE,PRVB, BTAI - etc all spiked from low ends $2.00-$4.00 to as high as $110 in past year with ZERO revenue and operating losses ranging from $24 million to $64 million- Things they had in common are low O/S between 23 million to 64 million and institutional ownership ranging from 22% to 85% -

Can't imagine a more compelling or exciting story than Leronlimab has to tell/sell, but it would be prudent to halve ( at least) the current outstanding shares. I'll set aside my opinion of NP's bodacious outbursts and hope that we'll be leaving the swamp for Shangri La ASAP-